Luzima confirms that it plans to have zero to minimal impact on royalty revenue through at least 2035 based on the Medicare Drug Price Negotiation Program Final Rule for IPAY 2029. Company announcement - FT.com.
Luzima confirms that it plans to have zero to minimal impact on royalty revenue through at least 2035 based on the Medicare Drug Price Negotiation Program Final Rule for IPAY 2029. Company announcement - FT.com.
Want to see every report in real time?
Hundreds of sources worldwide, translated into your language, with alerts for what matters to you.
Sign up free Already have an account? Log in